Compass Pathways (ADR) (CMPS)
Develops COMP360, an investigational psilocybin treatment with psychological support.
Something off on this page? Send us feedback.
Develops COMP360, a synthetic-psilocybin treatment paired with psychological support for treatment-resistant depression. Its clinical-stage model centers on regulatory development and potential commercialization, with no approved products.
COMP360 is a proprietary synthetic-psilocybin treatment administered with psychological support. Development has progressed from an international study in treatment-resistant depression to a Phase 3 program, while a Phase 2b/3 study addresses post-traumatic stress disorder. The program retains FDA Breakthrough Therapy and UK ILAP designations for treatment-resistant depression, but no indication has been approved.
Operations are based in London with a New York office, and work spans the United States, Europe, and the United Kingdom. Progress depends on completing clinical studies, regulatory approval, sufficient funding, trained healthcare professionals to monitor treatment, and eventual coverage and reimbursement.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 27, 2026 | Wells Fargo | Initiate | Rating: —Target: — | Target: $13 |
| Jul 20, 2026 | B.Riley Financial | Target | Target: — | Target: $17 |
| Jul 8, 2026 | Evercore ISI | Upgrade | Rating: — | |
| Jul 8, 2026 | Evercore ISI Group | Upgrade | ||
| Jul 7, 2026 | Stifel Nicolaus | Target | Target: — | Target: $21 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $433.3M · Total debt $54.6M · Total assets $504.6M · Shareholders' equity $84.5M
- Revenue
- $0
- Operating income
- −$52.4M
- Net income
- −$253.8M
No dividends on record.
| Institutions | ≈ 64.46% | 89.26M ADS | |
|---|---|---|---|
| 242 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 7.64% | 10.57M ADS | |
| 4 holders · as of Aug 5, 2026 | |||
| Other | ≈ 27.90% | 38.64M ADS | |
| remainder | |||
138.48M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Deep Track Capital, LPInstitution | 8.78% | 12.16M ADS | as of Jun 30, 2026 |
RTW Investments, LPInstitution | 7.73% | 10.70M ADS | as of Jun 30, 2026 |
Life Sciences N.V. ATAIInsider10 percent owner | 4.99% | 6.91M ordinary | filed Sep 27, 2024 |
Bit Capital GmbHInstitution | 4.58% | 6.35M ADS | as of Jun 30, 2026 |
Tang Capital Management LLCInstitution | 3.61% | 5.00M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- GH Research
5-MeO-DMT program in treatment-resistant depression
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Compass Pathways (ADR) | $14.78 | +0.03% | $2.03B | — | — | — | — |
| GH Research | $27.86 | −0.18% | $1.91B | — | — | — | — |